Forte Biosciences (FBRX) Income towards Parent Company (2016 - 2026)

Forte Biosciences (FBRX) has reported Income towards Parent Company for 11 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 41.39% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$107.2 million (down 140.3% YoY), while the FY2025 annual figure was -$73.5 million, down 2655.51% from the prior year.
• Income towards Parent Company grew to -$22.1 million in Q1 2026 per FBRX's latest filing, from -$24.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$2.8 million in Q1 2022 and bottomed at -$35.8 million in Q3 2025.
• Historically, Income towards Parent Company has averaged -$12.2 million across 5 years, with a median of -$8.7 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 90.32% — and 2025, when it plunged 313.47%.
• Forte Biosciences' Income towards Parent Company stood at -$5.0 million in 2022, then decreased by 28.12% to -$6.4 million in 2023, then slipped by 15.93% to -$7.4 million in 2024, then slumped by 231.19% to -$24.6 million in 2025, then climbed by 10.07% to -$22.1 million in 2026.
• Business Quant data shows FBRX's Income towards Parent Company at -$22.1 million in Q1 2026, -$24.6 million in Q4 2025, and -$35.8 million in Q3 2025.